OBJECTIVES: To describe characteristics of patients with schizophrenia receiving treatment with atypical injectable antipsychotics paliperidone palmitate and risperidone long-acting  as compared to other antipsychotics therapy at community behavioral health organizations (CBHOs) in the United States. METHODS: A longitudinal, noninterventional observational registry, Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations OUTcomes (REACH OUT) is collecting information on use of paliperidone palmitate, risperidone long-acting therapy (LAT), and  other antipsychotics by patients with schizophrenia or bipolar type I disorder receiving treatment at CBHOs. Patients are followed for 1 year, with assessments at baseline, 6, and 12 months. Sites use a Web-based data-collection tool to enter patient self-reports, interviewer assessments, and medical record abstractions. RESULTS: At time of analysis, baseline patient interview data from 114 patients with schizophrenia were collected at 10 sites in the following cohorts: 44% paliperidone palmitate injections, 33% risperidone injections, and 23% other antipsychotics. Patients in the paliperidone palmitate or risperidone LAT cohorts were older, on average,  than those receiving other antipsychotics: paliperidone palmitate, 41.2 years; risperidone LAT, 43.0; other antipsychotics, 35.0. Mean age at first psychiatric hospitalization was older for paliperidone palmitate (23.1) and risperidone LAT (24.4) than for other antipsychotics (20.1). Patients receiving the two injectable antipsychotics were more likely to be male (paliperidone palmitate, 70.0%; risperidone LAT, 73.7%; other antipsychotics, 69.2%) and single/never married (paliperidone palmitate, 78.0%; risperidone LAT, 78.9%; other antipsychotics, 69.2%). Patients treated with atypical antipsychotic injections were less likely to have private health insurance (paliperidone palmitate, 6.0%; risperidone LAT, 0.0%; other antipsychotics, 19.2%) and more likely to have Medicare (paliperidone palmitate, 60.0%; risperidone LAT, 60.5%; other antipsychotics, 23.1%) or Medicaid (paliperidone palmitate, 82.0%; risperidone LAT, 78.9%; other antipsychotics, 46.2%). CONCLUSIONS: Results suggest that patients in CBHOs receiving paliperidone palmitate and risperidone injections may differ from patients receiving other antipsychotics io sociodemographics.